MII oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Duration of stimulation (days) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Total dose of gonadotropins (IU) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Live birth or ongoing pregnancy sensitivity analysis ‐ PCOS (high‐responders) ‐ own oocytes ‐ early phase stimulation protocol ‐ frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in live birth or ongoing pregnancy sensitivity analysis ‐ PCOS… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Oocyte pick‐up cancellation sensitivity analysis ‐ PCOS (high‐responders)(micronised progesterone 100 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation sensitivity analysis ‐ PCOS… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Oocyte pick‐up cancellation · assisted reproduction technology cycles
Summary of findings table ‐ Progestogen 1 showed no clear difference in oocyte pick‐up cancellation ‐ Normo‐responders (MPA 4 mg versus… compared with progestogen 2 (low certainty).
2 findings from 1 review
Oocyte pick‐up cancellation ‐ Normo‐responders (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) ‐ Own oocytes ‐ Early phase stimulation protocol · assisted reproduction technology cycles
Summary of findings table ‐ Progestogen 1 showed no clear difference in oocyte pick‐up cancellation ‐ Normo‐responders (Dydrogesterone 20 mg… compared with progestogen 2 (moderate certainty).
1 finding from 1 review
Oocyte pick‐up cancellation · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation ‐ Normoresponders (micronised… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Ovulation rate Ultrasound evidence of collapsed follicle or mid‐luteal serum progesterone < 10 ng/mL · women with anovulatory infertility undergoing ovulation induction with clomiphene citrate
Human chorionic gonadotrophin showed no clear difference in ovulation rate Ultrasound evidence of collapsed follicle or… compared with no ovulation trigger (low certainty).
1 finding from 1 review
OR 0.99 [0.36, 2.77]
305 participants
Low
Improvement in pain score (up to nine months after treatment): progesterone versus placebo · women with chronic pelvic pain
Medical treatment probably leads to higher improvement in pain score at end of treatment: progesterone versus… compared with placebo (moderate certainty).
2 findings from 1 review
Weight gain · women with chronic pelvic pain
Medical treatment leads to higher weight gain: progesterone versus placebo compared with placebo (high certainty).
1 finding from 1 review
Bloatedness: progesterone versus placebo · women with chronic pelvic pain
Medical treatment leads to higher bloatedness: progesterone versus placebo compared with placebo (high certainty).
1 finding from 1 review
Peto OR 3.2 [1.37, 7.47]
85 participants
High
MBL (mL per cycle) · women with heavy menstrual bleeding
1 finding from 1 review
Number of days' bleeding · women with heavy menstrual bleeding
1 finding from 1 review
Quality of life · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Regression rate at 6 months · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes regression rate at 6 months compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Nausea · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes nausea over 6‐month compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Vaginal bleeding over 6‐month · women with atypical endometrial hyperplasia
Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).
1 finding from 1 review
Prevalence of dysmenorrhoea · women with symptomatic endometriosis
Mifepristone probably leads to lower prevalence of dysmenorrhoea compared with placebo (moderate certainty).
1 finding from 1 review